Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Better access to high quality biological medicines
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars

The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars.

The members of the BBA ensure access to high quality, safe and effective biosimilar medicines for UK patients. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and continuing optimised use of biosimilar medicines across the UK.

For more information about Biosimilars, please take a look at NHS England’s ‘What is a Biosimilar’ document.

Twitter

10.07.2018
Congratulations to @MattHancock on his appointment as Secretary of State for Health and Social Care
26.06.2018
RT @medicinesforEU: Learn more about @esno_web important work to transfer information re: switch management between similar #biological medicines! The launch of the guide will be followed by the the networking cocktail! See you tomorrow! #Biosimilars #AccessHealth https://t.co/Lile73VpSW
20.06.2018
RT @ScripIanS: #Brexit crumbs of comfort for life science firms: draft Withdrawal Agreement confirms that SPCs applied for in the UK during the transition period can be granted even if the procedure is still under way when the transition period ends. https://t.co/gPtPA20ZOT
24.05.2018
RT @ScripIanS: EU approves Sandoz' Zessly, a #biosimilar of Janssen/MSD's Remicade (infliximab). https://t.co/89dUxrDOG1 This is the fourth EU infliximab biosimilar approval, after Celltrion's Remsima, Hospira's Inflectra, and Samsung Bioepis' Flixabi.
17.05.2018
RT @Britishgenerics: Read our reaction to the @beisgovuk report on the impact of Brexit on the pharmaceutical sector - we agree patients could be impacted by lack of deal https://t.co/IqvDngb6zh